DBV Technologies to Participate in Upcoming March Investor Conferences
Globe Newswire (Wed, 4-Mar 4:30 PM ET)
Kepler Capital Sticks to Its Buy Rating for DBV Technologies (0QAJ)
TipRanks (Tue, 3-Mar 8:59 PM ET)
Globe Newswire (Tue, 3-Mar 4:30 PM ET)
Analysts Are Bullish on These Healthcare Stocks: Xtant Medical Holdings (XTNT), Apyx Medical (APYX)
TipRanks (Mon, 2-Mar 10:20 AM ET)
DBV Technologies Highlights Positive Phase 3 Peanut Patch Data
TipRanks (Mon, 2-Mar 8:17 AM ET)
Guggenheim Sticks to Their Buy Rating for DBV Technologies SA – American (DBVT)
TipRanks (Mon, 2-Mar 7:06 AM ET)
TipRanks (Mon, 2-Mar 7:00 AM ET)
Globe Newswire (Sat, 28-Feb 2:25 PM ET)
Globe Newswire (Tue, 10-Feb 4:30 PM ET)
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
Globe Newswire (Mon, 9-Feb 4:30 PM ET)
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
DBV Technologies S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol DBVT.
As of March 4, 2026, DBVT stock price climbed to $22.79 with 171,395 million shares trading.
DBVT has a beta of 0.28, meaning it tends to be less sensitive to market movements. DBVT has a correlation of 0.00 to the broad based SPY ETF.
DBVT has a market cap of $1.25 billion. This is considered a Small Cap stock.
Last quarter DBV Technologies S.A. - American Depositary Shares reported $3 million in Revenue and -$.24 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.52.
In the last 3 years, DBVT traded as high as $26.19 and as low as $2.20.
DBVT has outperformed the market in the last year with a price return of +475.5% while the SPY ETF gained +18.6%. DBVT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +75.4% and +10.1%, respectively, while the SPY returned +0.5% and +0.3%, respectively.
DBVT support price is $20.68 and resistance is $23.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DBVT shares will trade within this expected range on the day.